Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0720

+2.9%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	4/10/2015 9:22:06 AM
	2 Recommendations Recommended By Bob Miller Jack Russell of 13111

Slides from Provectus Panel Discussion Available Friday April 10, 2015 Provectus hosted a panel discussion on Thursday, April 9, 2015 at The Harvard Club of New York City. The panel updated investors on the newest scientific and regulatory developments on how the Company is harnessing the unique properties of Rose Bengal to safely and effectively fight cancer and dermatoses. Sanjiv Agarwala, MD, Professor of Medicine at Temple University School of Medicine and Chief of Medical Oncology at St. Luke's Hospital & Health Network, presented an overview of PV-10 and analysed clinical results through Phase 2 testing. Following Dr. Agarwala's presentation, Eric Wachter, PhD, Chief Technology Officer at Provectus, discussed the status of the currently ongoing Phase 3 study of PV-10 for the treatment of locally advanced cutaneous melanoma. Slides from Dr. Agarwala's presentation are available at: www.pvct.com/presentation/panel-Agarwala-2015/ Slides from Dr. Wachter's presentation are available at: www.pvct.com/presentation/panel-Wachter-2015/

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next